EUROPEAN drug regulators have said the benefits of diabetes drugs rosiglitazone and pioglitazone outweigh any potential cardiovascular risks, despite recent research.
However, the European Medicines Agency also said prescribing information should include a warning that, in patients with ischaemic heart disease, rosiglitazone should only be used after careful evaluation of individual risk.
Additionally, rosiglitazone and insulin should only be used together in exceptional cases and under close supervision.
Tracy Kelly, a care adviser at Diabetes UK, said nurses should screen and monitor patients taking the drugs. ‘But the risks are so small in the grand scheme of things,’ she added.